Dexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches

Simple item page
dc.contributor.authorCastillo, Rodrigo L.
dc.contributor.authorIbacache, Mauricio
dc.contributor.authorCarrasco-Pozo, Catalina
dc.contributor.authorCortínez, Ignacio
dc.contributor.authorFarías, Jorge G.
dc.contributor.authorCarrasco, Rodrigo A.
dc.contributor.authorRamos, Daniel
dc.contributor.authorBenavente, Rafael
dc.contributor.authorHenríquez Torres, Daniela
dc.contributor.authorMéndez, Aníbal
dc.contributor.authorVargas, Patricio
dc.date.accessioned2021-07-29T21:06:02Z
dc.date.available2021-07-29T21:06:02Z
dc.date.issued2020-02
dc.description.abstractDexmedetomidine (DEX) is a highly selective α2-adrenergic agonist with sedative and analgesic properties, with minimal respiratory effects. It is used as a sedative in the intensive care unit and the operating room. The opioid-sparing effect and the absence of respiratory effects make dexmedetomidine an attractive adjuvant drug for anesthesia in obese patients who are at an increased risk for postoperative respiratory complications. The pharmacodynamic effects on the cardiovascular system are known; however the mechanisms that induce cardioprotection are still under study. Regarding the pharmacokinetics properties, this drug is extensively metabolized in the liver by the uridine diphosphate glucuronosyltransferases. It has a relatively high hepatic extraction ratio, and therefore, its metabolism is dependent on liver blood flow. This review shows, from a basic clinical approach, the evidence supporting the use of dexmedetomidine in different settings, from its use in animal models of ischemia-reperfusion, and cardioprotective signaling pathways. In addition, pharmacokinetics and pharmacodynamics studies in obese subjects and the management of patients subjected to mechanical ventilation are described. Moreover, the clinical efficacy of delirium incidence in patients with indication of non-invasive ventilation is shown. Finally, the available evidence from DEX is described by a group of Chilean pharmacologists and clinicians who have worked for more than 10 years on DEX.es
dc.identifier.citationFrontiers in Pharmacology, 2020 february, vol.10, art. 1641es
dc.identifier.urihttps://doi.org/ 10.3389/fphar.2019.01641es
dc.identifier.urihttp://hdl.handle.net/11447/4213
dc.language.isoenes
dc.subjectDexmedetomidinees
dc.subjectCardiaces
dc.subjectPreconditioninges
dc.subjectPharmacokineticses
dc.subjectNon-invasive mechanical ventilationes
dc.subjectSedative and analgesic propertieses
dc.titleDexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approacheses
dc.typeArticlees

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dexmedetomidine Improves Cardiovascular...atients_ Basic and Clinical Approaches.pdf
Size:
720.26 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services